FluBuATG
Phase 1 Completed
20 enrolled
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
14 enrolled
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
Phase 1 Completed
70 enrolled
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 3 Completed
256 enrolled 13 charts
AML/MDS/JMML
Phase 1 Completed
18 enrolled
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
18 enrolled 16 charts
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
14 enrolled
Allogeneic Stem Cell Transplantation for Children With CML
Phase 2/3 Completed
13 enrolled
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2 Completed
24 enrolled 8 charts
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Phase NA Completed
87 enrolled 10 charts
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase 1/2 Completed
47 enrolled 8 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Cord Blood Expansion on Mesenchymal Stem Cells
Phase 1 Completed
98 enrolled
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Phase NA Completed
62 enrolled 14 charts
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
Phase 2 Completed
63 enrolled 9 charts
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Phase 2 Completed
44 enrolled 13 charts
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
14 enrolled 22 charts
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
Phase 2 Completed
42 enrolled 13 charts
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Phase NA Completed
100 enrolled 10 charts
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Phase 2 Completed
21 enrolled 13 charts
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Phase 2 Completed
48 enrolled 12 charts
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Phase 1 Completed
33 enrolled
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Phase 2 Completed
23 enrolled
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
Phase 2 Completed
6 enrolled 3 charts
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Phase 2 Completed
24 enrolled 13 charts
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
Phase 2 Completed
29 enrolled 6 charts